Made in China: The international supply of illicit Semaglutide and weight-loss medicines online
Background: The use of GLP-1 medicines for weight-loss purposes is increasingly widespread. While these drugs are available as prescription medicines in the UK, there is an expansive illicit market for their supply operating online. This study investigates the scope and impact of illicit weight-loss...
Saved in:
| Main Authors: | Luke A. Turnock, Evelyn Hearne, Lambros Lazuras |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-12-01
|
| Series: | Emerging Trends in Drugs, Addictions, and Health |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S266711822400028X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Semaglutide, liraglutide and tirzepatide: Comparison of effectiveness in the treatment of obesity – a literature review
by: Karolina Baran, et al.
Published: (2024-12-01) -
Management of obesity with semaglutide or metformin in patients with antipsychotic-induced weight gain (MOSA): a non-randomised open-label pilot study
by: Bea Campforts, et al.
Published: (2024-11-01) -
Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado
by: Michael J. DiStefano, et al.
Published: (2025-12-01) -
Real-world effectiveness of Semaglutide treatment on weight loss maintenance after weight loss in patients with obesity or overweight and diabetes
by: Michela Del Prete, et al.
Published: (2025-01-01) -
Effectiveness and Side Effect Incidence in a Real-World Digital Weight-Loss Service Using Compounded Semaglutide: A Retrospective Comparative Study
by: Louis Talay, et al.
Published: (2024-10-01)